Open-label Pilot Study of Abatacept for the Treatment of Vitiligo

Status Active, not recruiting

Clinical Trial Summary

Vitiligo is a chronic autoimmune disease with evidence of CTLA-4 involvement. We are performing a pilot study for the treatment of new onset or actively progressing vitiligo with abatacept to determine if weekly self-injections of medication lead to clinical improvement in vitiligo lesions.

Clinical Trial Description

Abatacept has been shown to decrease T cell activity and reduce symptoms associated with rheumatoid arthritis. Similar pathways have been shown to be involved in vitiligo. Therefore, we are recruiting 10 adult patients with active vitiligo who meet specific inclusion and exclusion criteria to receive self-administered injections of abatacept weekly starting at week 0 and continuing until week 24. A 32 week follow-up visit will be performed to evaluate secondary endpoints as well. We will be monitoring patients to see if skin lesions of vitiligo stop spreading and start to repigment with continued treatment. ;

Study Design

Related Conditions & MeSH terms

Vitiligo

Clinical Trial Details

NCT number	NCT02281058
Study type	Interventional
Source	Brigham and Women's Hospital
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	January 2015
Completion date	May 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05298033` - Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo	Phase 2
Recruiting	`NCT05872477` - Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas	Phase 2
Terminated	`NCT04374435` - Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo	N/A
Completed	`NCT04103060` - Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo	Phase 2
Terminated	`NCT04271501` - Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions	N/A
Completed	`NCT04530344` - Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo	Phase 3
Not yet recruiting	`NCT05008887` - Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo	Phase 4
Terminated	`NCT02191748` - Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo	Phase 2/Phase 3
Terminated	`NCT01262547` - A New Micrografting Technique for Vitiligo	Phase 2
Completed	`NCT01382589` - Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo	Phase 2
Active, not recruiting	`NCT04971200` - Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo	Early Phase 1
Completed	`NCT04872257` - Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo	N/A
Completed	`NCT04547998` - Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions	N/A
Not yet recruiting	`NCT04039451` - Prevalence of Psoriasis and Vitiligo in Assiut Governorate, Egypt
Not yet recruiting	`NCT03611348` - Microneedling and Latanoprost in Acrofacial Vitiligo	Phase 2/Phase 3
Recruiting	`NCT03199664` - Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo	Phase 4
Recruiting	`NCT03340155` - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases	N/A
Completed	`NCT03249064` - Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo	N/A
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting	`NCT04246372` - Tofacitinib for Immune Skin Conditions in Down Syndrome	Phase 2